| Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors A Bamias, E Kastritis, C Bamia, LA Moulopoulos, I Melakopoulos, ... J Clin Oncol 23 (34), 8580-7, 2005 | 1602 | 2005 |
| Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid MA Dimopoulos, E Kastritis, C Bamia, I Melakopoulos, D Gika, M Roussou, ... Annals of Oncology 20 (1), 117-120, 2009 | 576 | 2009 |
| Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid MA Dimopoulos, E Kastritis, A Anagnostopoulos, I Melakopoulos, D Gika, ... haematologica 91 (7), 968-971, 2006 | 462 | 2006 |
| Thalidomide and dexamethasone combination for refractory multiple myeloma MA Dimopoulos, K Zervas, G Kouvatseas, E Galani, V Grigoraki, ... Annals of Oncology 12 (7), 991-995, 2001 | 420 | 2001 |
| Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide MA Dimopoulos, A Anagnostopoulos, MC Kyrtsonis, K Zervas, C Tsatalas, ... Journal of Clinical Oncology 25 (22), 3344-3349, 2007 | 338 | 2007 |
| Treatment of Waldenstrom’s macroglobulinemia with rituximab MA Dimopoulos, C Zervas, A Zomas, C Kiamouris, NA Viniou, V Grigoraki, ... Journal of Clinical Oncology 20 (9), 2327-2333, 2002 | 295 | 2002 |
| Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the … E Kastritis, K Zervas, A Symeonidis, E Terpos, S Delimbassi, ... Leukemia 23 (6), 1152-1157, 2009 | 240 | 2009 |
| Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study … A Bamias, G Aravantinos, C Deliveliotis, D Bafaloukos, C Kalofonos, ... Journal of Clinical Oncology 22 (2), 220-228, 2004 | 218 | 2004 |
| Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents E Kastritis, A Anagnostopoulos, M Roussou, D Gika, C Matsouka, ... haematologica 92 (4), 546-549, 2007 | 204 | 2007 |
| Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European … MA Dimopoulos, R García-Sanz, M Gavriatopoulou, P Morel, ... Blood, The Journal of the American Society of Hematology 122 (19), 3276-3282, 2013 | 202 | 2013 |
| Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma MA Dimopoulos, G Hamilos, A Zomas, D Gika, E Efstathiou, V Grigoraki, ... The Hematology Journal 5 (2), 112-117, 2004 | 192 | 2004 |
| Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents MA Dimopoulos, S Delimpasi, E Katodritou, A Vassou, MC Kyrtsonis, ... Annals of oncology 25 (1), 195-200, 2014 | 175 | 2014 |
| Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma LA Moulopoulos, D Gika, A Anagnostopoulos, K Delasalle, D Weber, ... Annals of Oncology 16 (11), 1824-1828, 2005 | 156 | 2005 |
| Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix CA Papadimitriou, K Sarris, LA Moulopoulos, G Fountzilas, ... Journal of clinical oncology 17 (3), 761-761, 1999 | 132 | 1999 |
| Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study E Kastritis, M Gavriatopoulou, MC Kyrtsonis, M Roussou, E Hadjiharissi, ... Blood, The Journal of the American Society of Hematology 126 (11), 1392-1394, 2015 | 129 | 2015 |
| Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study MA Dimopoulos, CA Papadimitriou, V Georgoulias, LA Moulopoulos, ... Gynecologic oncology 78 (1), 52-57, 2000 | 115 | 2000 |
| Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents M Roussou, E Kastritis, D Christoulas, M Migkou, M Gavriatopoulou, ... Leukemia research 34 (10), 1395-1397, 2010 | 110 | 2010 |
| Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients … LA Moulopoulos, MA Dimopoulos, E Kastritis, D Christoulas, ... American journal of hematology 87 (9), 861-864, 2012 | 105 | 2012 |
| Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group A Bamias, C Deliveliotis, G Fountzilas, D Gika, A Anagnostopoulos, ... Journal of clinical oncology 22 (11), 2150-2154, 2004 | 105 | 2004 |
| Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure … MA Dimopoulos, M Roussou, M Gavriatopoulou, E Psimenou, ... American journal of hematology 91 (5), 499-502, 2016 | 99 | 2016 |
